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Summary
OBJECTIVE: To assess vaccination coverage for adults
living in Switzerland.
METHODS: Through a media campaign, the general pop-
ulation was invited during 1 month to bring their vaccin-
ation certificates to the pharmacies to have their immun-
isation status evaluated with the software viavac©, and to
complete a questionnaire.
RESULTS: A total of 496 pharmacies in Switzerland par-
ticipated in the campaign, of which 284 (57%) submitted
valid vaccination information. From a total of 3,634 parti-
cipants in the campaign, there were 3,291 valid cases (par-
ticipants born ≤1992) and 1,011 questionnaires completed.
Vaccination coverage for the participants was 45.9% and
34.6% for five and six doses of diphtheria, 56.4% and
44.0% for tetanus and 66.3% and 48.0% for polio, respect-
ively. Coverage estimates for one and two doses of measles
vaccine were 76.5% and 49.4%, respectively, for the birth
cohort 1967–1992 and 4.0% and 0.8%, respectively, for the
cohort ≤1966. There was a significant difference in cover-
age for most vaccinations between the two aforementioned
birth cohorts. A plot of the measles vaccine coverage over
time shows that the increase in coverage correlated with
policy changes in the Swiss Immunisation Schedule.
CONCLUSIONS: Despite selection bias and low particip-
ation, this study indicates that vaccination coverage for the
basic recommended immunisations in the adult population
in Switzerland is suboptimal. More efforts using various
means and methods are needed to increase immunisation
coverage in adolescents before they leave school. An es-
tablished method to determine vaccination coverage for the
general population could provide invaluable insights into
the effects of changes in vaccination policies and disease
outbreaks.
Key words: adult vaccination coverage; pharmacy;
measles; Switzerland; immunisation registry
Introduction
Vaccination coverage of children in Switzerland has been
well established, with an active monitoring system that al-
lows coverage of toddlers aged 24–35 months and children
8 and 16 years of age to be determined every 3 years at
the cantonal and national levels [1–3]. Owing to the loss
of contact, immunisation coverage in adults cannot be de-
termined routinely, a situation typical of many developed
countries [4]. Furthermore, Lee et al. (2003) showed that
approximately up to one-third of healthy Swiss employees
were unaware of their vaccination status [5].
As a result of their extended business hours and convenient
locations, pharmacies can alleviate this loss of contact,
as they are an easily accessible healthcare facility. More
than 300,000 customers walk into a pharmacy every day
in Switzerland [6]. As a healthcare professional, the phar-
macist is obligated by Swiss law to, inter alia, assist pa-
tients and other healthcare professionals in all pharmaceut-
ical issues and to assume tasks to promote and maintain
health and to prevent diseases [7]. Pharmacists in several
countries around the world, including the United States,
United Kingdom and Portugal, have been acting as advoc-
ates for immunisations and many have been allowed to
vaccinate for over a decade [8–12]. In Switzerland, vac-
cinations are currently not yet associated with pharmacies,
although it is currently possible to get certain vaccinations
in five Cantons (Neuchâtel, Zurich, Ticino, Basel-Country,
Solothurn), with more to follow.
For their Public Health Campaign 2009, in collaboration
with the Institute of Social and Preventive Medicine
(ISPM) at the University of Zurich, pharmaSuisse (the
Swiss Association of Pharmacists) introduced vaccination
counselling in the pharmacies in Switzerland by means of
a national media campaign. During 1 month, the general
population was invited to bring their vaccination certific-
ates to the pharmacies, to have their immunisation status
evaluated and to complete a questionnaire regarding their
vaccination perceptions.
This campaign offered a unique opportunity to determine
the vaccination coverage of the adult population in
Switzerland, to examine the perceptions of vaccinations
and to evaluate the feasibility of establishing a national
method to monitor vaccination coverage. The Swiss Feder-
al Office of Public Health (FOPH) has set a goal to elimin-
ate measles in Switzerland by 2015. We also used the data-
base, established during the campaign, to investigate epi-
demiological correlations between (1.) changes in measles
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vaccination policies, measles outbreaks and vaccination
coverage and (2.) coverage with measles-containing vac-
cine (MCV) introduced in Switzerland in 1966.
Methods
viavac© 2009, Version 3.16
The viavac© software uses algorithms based on the Swiss
national vaccination recommendations. It allows a quick
and accurate assessment of the vaccination status of any in-
dividual [13]. Data compiled in the viavac© database in-
cluded name, date of birth, gender, zip code, city, nation-
ality (default = Swiss) and serology information as well as
the dates of vaccinations for diphtheria (Di), tetanus (Te),
pertussis (Per), polio (Pol), Haemophilus influenzae type
B (Hib), measles, mumps, rubella, hepatitis B (HB), vari-
cella, pneumococcus, meningococcus type C, tick-borne
encephalitis (TBE), hepatitis A (HA), human papillomavir-
us (HPV) and a limited number of vaccinations recommen-
ded for travelling. In addition, viavac© gave a recommend-
ation when the vaccination status was not up to date.
Selection of pharmacies
Before the campaign began, all member pharmacies of
pharmaSuisse were informed of this new public health
campaign and were invited to participate. In order to pre-
pare for the campaign, the pharmacists in the participating
pharmacies were obligated to participate in a two-part
workshop, which was conducted in French or German, de-
pending on the location. The first part refreshed the phar-
macists' medical knowledge regarding vaccinations (im-
munology, side effects, coverage) whereas the second tech-
nical part involved used of the viavac© software for enter-
ing and exporting data.
Campaign
Through media exposure, the general population was in-
vited to bring their vaccination certificate to the pharmacy
to have their immunisation status evaluated. The media
campaign included national advertisements via radio, tele-
vision, magazines and posters emphasising the importance
of vaccination and keeping it up to date. From 12th October
to 7th November 2009, interested participants were coun-
selled on their vaccination status by a pharmacist. The re-
commended price for this consultation during the campaign
was CHF 19.00. Participants were also asked to complete
a questionnaire which included four questions pertaining to
measles and HPV vaccination.
At the end of the campaign, pharmacies were requested to
send their exported viavac© data by email and the ques-
tionnaires by mail to ISPM for processing and evaluation.
If necessary, pharmaSuisse sent the pharmacies three re-
minders to transmit the data. Follow-ups were done by tele-
phone or email by ISPM to all those who sent invalid data
(wrong format) or incomplete data (only questionnaires or
only viavac© files).
Analysis
The viavac© files and questionnaires were anonymous,
therefore names were not available. Information collected
from the participants included: date of birth, gender, zip
code, city and vaccination and serology information. Only
data for participants aged ≥18 years (year of birth ≤1992)
and whose vaccination data were extracted from a vaccina-
tion certificate were considered in the analysis.
Calculated coverage estimates were not weighted since the
data collected did not stem from a sampling survey. To de-
termine coverage estimates, we grouped the data into two
birth cohorts: individuals who were born before 1967 and
individuals born between 1967 and 1992. To study how
the year of birth affected MCV coverage, the birth cohorts
were defined as: those born in or before 1966, 1967–1971,
1972–1976, 1977–1981, 1982–1986, and 1987–1992. The
vaccination status in 2009 was considered. 95% Wald con-
fidence intervals were also calculated for coverage estim-
ates. Data processing and analysis were done in MySQL
(Community Server, GPL, version 5.511) and R (version
2.14.0, The R Foundation for Statistical Computing) [14].
Results
Participation
Of the 1,724 pharmacies in Switzerland, 1,351 (78%) were
members of pharmaSuisse in 2009 (table 1). A total of
496 (36.7%) member pharmacies of pharmaSuisse bought
the software for the campaign, with distribution across lin-
guistic region being 312 (63%) in the German-, 154 (31%)
in the French-, and 30 (6%) in the Italian-speaking regions.
Of these, 284 (57%) submitted valid vaccination informa-
tion and 55 (11%) had either technical problems exporting
the data or simply did not have any customers interested in
the campaign. Of the 284 pharmacies involved in the cam-
paign, 219 (77%) of those in the German-speaking region
of Switzerland involved in the campaign, sent a valid via-
vac©file, whereas there were only 51 (18%) in the French-
and 14 (5%) in the Italian-speaking parts.
Figure 1
(a) Measles-containing vaccine (MCV) coverage for various birth
cohorts at one and two doses; n represents the size of the birth
cohort. (b) Number of participants according to year and birth
cohort ≤1966, 1967‒1992 and ≤1992. Starting in 1993 the curve is
flat since no new participants were considered. (c) MCV coverage
over time for birth cohorts ≤1966, 1967–1992 and ≤1992. Arrows
labelled with (+) indicate when changes to the measles / measles-
mumps-rubella recommendations were made in the Swiss
Immunization Schedule and arrows labelled with (*) show the
occurrences of large measles outbreaks in Switzerland that were
published. The bars on the coverage data represent Wald
confidence intervals.
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From a total of 3,634 participants in the campaign, 3,291
(90.6%) valid cases (participants ≥18 years) were exported
from viavac© and 1,011 (27.8%) questionnaires com-
pleted.
Vaccination coverage
Vaccination coverage for participants born ≤1992 was:
45.9% and 34.6% for five and six doses of Di, 56.4% and
44.0% for Te and 66.3% and 48.0% for Pol, respectively
(table 2). Coverage estimates for one and two doses of
MCV were 76.5% and 49.4%, respectively, for those born
1967–1992, and 4.0% and 0.8%, respectively, for those
born ≤1966; 35.1% of the participants were vaccinated
with two doses against HA and 27.7% with three doses
against HB. Almost one-quarter (22.3%) had received at
least three doses of the vaccine against TBE. Except for
polio at six doses, influenza, HA and TBE vaccinations, in-
dividuals in the birth cohort 1967–1992 had a much higher
coverage for most vaccinations than those from the cohort
≤1966.
For comparative purposes, the national vaccination cover-
age for adolescents aged 16 years (birth cohort 1991) living
in Switzerland from the Swiss National Vaccination Cover-
age Survey (SNVCS) from 2005–2007 [2] is also displayed
in table 2. Except for Di, Te and Pol at six doses, cover-
age for the teenagers in the SNVCS was consistently higher
than those from the birth cohort 1967–1992.
Figure 1 shows MCV coverage at one and two doses by
time and birth cohort after 1966, with the number of par-
ticipants in the campaign according to time. According to
figure 1a, the younger birth cohorts had higher coverage
than the older ones, with the slope saturating at about 95%
after the birth cohort 1982–86 at one dose. Figure 1c shows
MCV coverage together with the changes to the recom-
mendations for measles-mumps-rubella (MMR) and mono-
valent measles vaccines, and the occurrences of large
measles outbreaks in Switzerland since 1966. Measles vac-
cine coverage at one dose increased quickly for the birth
cohort 1967–1992 after 1971, when MMR vaccine was
first introduced, until approximately 1993, when the slope
levelled off. Coverage with two doses also began to in-
Table 1: Characteristics of the pharmacies, the participants in the campaign and the population of Switzerland in 2009.
Linguistic regiona
No. Average D F I
Swiss population (age ≥18)b 6,416,153 – 71% 25% 4%
Pharmacies
Pharmacies in Switzerlandc 1,724 – 50% 39% 11%
Membership in pharmaSuissec 1,351 78%d 59% 29% 13%
Campaign
Campaign pharmacies 496 – 63% 31% 6%
Pharmacies which delivered valid files 284 57%e 77% 18% 5%
Participants 3,634 – 84% 13% 3%
Average number of participants per pharmacy which sent files 12.8 14 9.2 7.1
Demographic information for the participants
(Percentages reflect distribution of the demographic variable for each linguistic region)
Vaccination data (viavac©) 3,291
Sex
Female 63%f 63% 66% 66%
Male 37% 37% 34% 34%
Birth cohort
1967–1992 43%g 40% 59% 71%
≤1966 57% 60% 41% 29%
Questionnaires 1,011
Sex
Female 66% 66% 64% 74%
Male 34% 34% 36% 26%
Birth cohort
1967–1992 32% 29% 49% 74%
≤1966 68% 71% 51% 26%
Demographic information for Switzerland 2009b 6,416,153
Sex
Female 51% 51% 52% 52%
Male 49% 49% 48% 48%
Birth cohort
1967–1992 46% 45% 47% 42%
≤1966 54% 55% 53% 58%
a Linguistic region: D German, F French and I Italian.
b Reference: Federal Statistical Office (FSO), 2009.
c Reference: pharmaSuisse, 2009.
d Percentage is related to total pharmacies.
e Percentage is related to campaign pharmacies.
f Distribution of gender in campaign differs from Swiss population (p <0.001).
g Distribution of birth cohorts in campaign differs from Swiss population (p= 0.008).
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crease in 1985 and in 1996, possibly as a result of the two
large measles outbreaks in 1987 and 1996 during this time.
Although a second dose of measles vaccine was first re-
commended in 1996, the increase in coverage at two doses
before this date suggested that doctors vaccinated their pa-
tients again during an outbreak, regardless of whether re-
cords showed that the person had been already vaccinated
once.
Perceptions of measles and HPV vaccination
Answers to the four questions in table 3 examining disease
perceptions indicated that more women than men con-
sidered measles to be dangerous. The respondents also
stated that it made sense to vaccinate against measles, that
measles vaccination should be mandatory and that HPV
vaccination made sense. Adults born 1967–1992 agreed
more often that measles was dangerous and that vaccina-
tion made sense as compared to those in the birth cohort
≤1966. A total of 69.0% of the population stated that
measles was a dangerous disease (69.7% from the German-
speaking region, 67.3% from the French-speaking region
and 57.9% from the Italian-speaking region), compared
with 2.5% who found it not dangerous and 14.7% who
found it not very dangerous. A total of 76.9% thought
measles vaccination made sense (D: 75.8%, F: 82.2%, I:
86.8%); however, only 43.7% believed it should be man-
datory (D: 42.8%, F: 49.5%, I: 50.0%). For HPV vaccin-
ation, more adults in the French- and Italian-speaking re-
gions thought vaccination made sense than in the German-
speaking region (D: 54.7%, F: 76.2%, I: 60.5%).
Discussion
This public health campaign in 2009 was the first national
attempt by pharmaSuisse to introduce vaccination coun-
selling in the pharmacies in Switzerland using the software
viavac©. Although a generalisation of the vaccination cov-
erage estimates obtained from the campaign to the entire
Swiss population was not possible as a result of selection
bias and low participation, the results obtained were inter-
esting and should be further investigated.
As visits to physicians decline and vaccination coverage
data become scarce once adolescents graduate from school,
it is important to find alternative sources to increase cover-
age data. Because of their accessibility, convenient hours,
location and rising acceptance as alternative immunisation
providers, pharmacists can make an impact on public
health, by counselling on and also administering vaccin-
ations [8–12, 15]. During the campaign month, approx-
imately 3,600 individuals were interested in having their
immunisation status evaluated. Previous studies have con-
firmed that vaccinations provided in pharmacies combined
the productivity and efficiency of mass vaccination clinics,
with the attention to detail and personalisation of a sched-
uled primary care visit, while increasing the vaccine cover-
age rates [9, 16–19]. Recently, there have been discussions
about allowing pharmacists to vaccinate in Switzerland.
The authorisation to vaccinate lies solely in the jurisdic-
tion of each canton. Several cantons have already author-
ised pharmacists with the required training as provided in
the postgraduate certificate Foederatio Pharmaceutica Hel-
vetiae (FPH) to vaccinate clients in the pharmacy. Since
its establishment in 2012, approximately 154 pharmacists
have obtained this certificate.
Vaccination data obtained from this campaign could be
useful to estimate coverage level in the adult population.
When comparing the birth cohort 1967–1992 with the
school children (birth cohort 1991) from the SNVCS
2005–07 data, coverage estimates for Di, Te and Pol vac-
cination in the campaign group for the birth cohort
1967–1992 were significantly lower than the estimates for
the adolescents in the SNVCS at 5 doses (see table 2). This,
however, was reversed at six doses, since a booster shot
was required for tetanus every 10 years until recently and
because of travel to countries where vaccinations, espe-
cially against polio, are recommended.
HA vaccine coverage is about 35%, similar to the preval-
ence of hepatitis A virus risk factors calculated for Switzer-
land [20]. As HA is recommended for those travelling
abroad regardless of age, the difference in coverage
between the two birth cohorts (≤1966 and 1967–1992) be-
came smaller. For HB, a significant difference between the
younger and older age groups was observed (see table 2)
as HB vaccination has been included in the recommended
Swiss Immunisation Schedule (SIS) since 1998, targeting
the pre-teen age group owing to their potential increased
risk behaviours [21]. Furthermore, HB vaccinations are
offered free of charge to students in school.
Especially notable was the MCV coverage, which was very
low for the cohort ≤1966 since many were assumed to have
acquired the antibodies through natural infection during
childhood. The low MCV coverage (76.5% at one dose and
49.4% at two doses) for the cohort 1967–1992 compared
with 76.6% at two doses for the 16–year olds (birth cohort
1991) indicates that much more effort needs to be expen-
ded to increase coverage for the teenagers since the level
did not increase once they left school. Moreover, about
one-quarter of those born 1967–1992 were not vaccinated
against measles, this being a conservative estimate because
of selection bias. A recent survey conducted by the FOPH
estimated that MCV coverage for 20–29-year-olds living in
Switzerland was 93% at one dose and 77% at two doses,
which was also observed in our study as shown in figure 1a
for birth cohorts 1982–1992 [22].
This study also shows the potential of establishing a central
immunisation registry in Switzerland. Just recently, the
Swiss Parliament approved further investment into a na-
tional electronic system to maintain patient information,
such as vaccination data. Currently, individuals are able
to upload their vaccination data on the Internet platform
www.myvaccines.ch. The FOPH also promoted this ser-
vice during the European Immunisation Week as part of
their measles elimination campaign [23]. However, be-
cause the national immunisation coverage could be over-
estimated as a result of selection bias, it is vital that par-
ticipation in such a system is high and representative of
the population to yield valid epidemiological data. Further-
more, a central immunisation registry could not only mon-
itor the effects of the changes in the national recommend-
ations for immunisation and occurrences of outbreaks as
reflected in the figure 1, but could also detect variation in
vaccine acceptance by the population. After the steep in-
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crease of MCV coverage at one dose after 1971, which
was probably due to the FOPH introduction of MMR into
the SIS following the introduction of the first monovalent
measles vaccine in 1966, the slope began to level off in
1993 as a result of (1.) no new birth cohort entering the
database and (2.) the slight increase in the slope due to
catch-up shots among the teenagers and adults, reflecting
the changes in the recommendations in the SIS. The data
Table 2: Vaccination coverage (in %) and 95% confidence intervals (CIs) of adults in birth cohort 1967–1992 and those in birth cohort ≤1966 from campaign. The last
column is the coverage rate of teenagers 16 years of age from the Swiss National Vaccination Coverage Survey 2005–2007. Coverage is not weighted.
Campaign SNVCS
Adults (birth cohorts) Teenagers
No. of doses 1967–1992
(n = 1,423)
≤1966
(n = 1,868)
≤1992
(n = 3,291)
16 years old
(n = 9,301)
95% CI 95% CI 95% CI 95% CI
Diphtheria 0 9.2 (7.7–10.7) 16.9 (15.2–18.6) 13.6 (12.4–14.8) 0.9 (0.7–1.1)
≥1 90.8 (89.3–92.3) 83.1 (81.4–84.8) 86.4 (85.2–87.6) 99.1 (98.9–99.3)
≥4 82.6 (80.6–84.5) 34.3 (32.1–36.4) 55.2 (53.5–56.8) 93.7 (93.2–94.2)
≥5 76.0 (73.8–78.3) 23.0 (21.1–24.9) 45.9 (44.2–47.6) 87.9 (87.2–88.5)
≥6 62.1 (59.5–64.6) 13.8 (12.2–15.3) 34.6 (33.0–36.3) 61.4 (60.4–62.3)
Tetanus 0 8.4 (6.9–9.8) 9.8 (8.5–11.1) 9.2 (8.2–10.2) 0.7 (0.5–0.8)
≥1 91.6 (90.2–93.1) 90.2 (88.9–91.5) 90.8 (89.8–91.8) 99.3 (99.2–99.5)
≥4 83.6 (81.7–85.6) 51.9 (49.7–54.2) 65.6 (64.0–67.3) 94.2 (93.8–94.7)
≥5 79.1 (77.0–81.2) 39.1 (36.9–41.3) 56.4 (54.7–58.1) 88.5 (87.8–89.1)
≥6 66.8 (64.3–69.2) 26.7 (24.7–28.7) 44.0 (42.3–45.7) 62.1 (61.1–63.1)
Pertussis 0 24.2 (22.0–26.5) 78.5 (76.6–80.3) 55.0 (53.3–56.7) 10.6 (9.9–11.2)
≥1 75.8 (73.5–78.0) 21.5 (19.7–23.4) 45.0 (43.3–46.7) 89.4 (88.8–90.1)
≥2 73.0 (70.7–75.3) 19.3 (17.5–21.1) 42.5 (40.8–44.2) 86.6 (85.9–87.3)
≥3 70.7 (68.3–73.1) 17.6 (15.8–19.3) 40.5 (38.9–42.2) 84.0 (83.3–84.7)
Polio 0 12.0 (10.3–13.7) 10.0 (8.6–11.3) 10.9 (9.8–11.9) 1.0 (0.8–1.2)
≥1 88.0 (86.3–89.7) 90.0 (88.7–91.4) 89.2 (88.1–90.2) 99.0 (98.8–99.2)
≥4 80.0 (78.0–82.1) 70.2 (68.2–72.3) 74.5 (73.0–76.0) 93.8 (93.3–94.3)
≥5 73.7 (71.4–75.9) 60.8 (58.5–63.0) 66.3 (64.7–67.9) 84.8 (84.1–85.5)
≥6 46.7 (44.1–49.3) 48.9 (46.6–51.1) 48.0 (46.2–49.7) 19.2 (18.4–20.0)
Measles 0 23.5 (21.3–25.7) 96.0 (95.1–96.9) 64.7 (63.0–66.3) 6.2 (5.7–6.7)
≥1 76.5 (74.3–78.7) 4.0 (3.1–4.9) 35.3 (33.7–37.0) 93.8 (93.3–94.3)
≥2 49.4 (46.8–52.0) 0.8 (0.4–1.2) 21.8 (20.4–23.2) 76.6 (75.7–77.4)
Mumps 0 37.3 (34.8–39.8) 96.7 (95.9–97.5) 71.0 (69.5–72.6) 7.0 (6.5–7.5)
≥1 62.7 (60.2–65.2) 3.3 (2.5–4.1) 29.0 (27.4–30.5) 93.0 (92.5–93.5)
≥2 26.2 (23.9–28.5) 0.6 (0.2–0.9) 11.7 (10.6–12.8) 75.6 (74.8–76.5)
Rubella 0 18.6 (16.5–20.6) 76.0 (74.1–78.0) 51.2 (49.5–52.9) 7.0 (6.4–7.5)
≥1 81.5 (79.4–83.5) 24.0 (22.0–25.9) 48.8 (47.1–50.5) 93.0 (92.5–93.6)
≥2 39.4 (36.8–41.9) 2.0 (1.4–2.7) 18.2 (16.9–19.5) 75.4 (74.5–76.2)
Hepatitis A 0 51.9 (49.3–54.5) 63.0 (60.8–65.1) 58.2 (56.5–59.8) 83.5 (82.8–84.3)
≥1 48.1 (45.5–50.7) 37.0 (34.9–39.2) 41.8 (40.2–43.5) 16.5 (15.7–17.2)
≥2 41.5 (39.0–44.1) 30.3 (28.2–32.3) 35.1 (33.5–36.8) 13.4 (12.7–14.1)
Hepatitis B 0 41.6 (39.0–44.2) 79.0 (77.2–80.9) 62.8 (61.2–64.5) 30.6 (29.7–31.6)
≥1 58.4 (55.8–61.0) 21.0 (19.1–22.8) 37.2 (35.5–38.8) 69.4 (68.4–70.3)
≥2 55.7 (53.1–58.2) 19.2 (17.4–20.9) 34.9 (33.3–36.6) 65.0 (64.0–66.0)
≥3 42.5 (39.9–45.0) 16.5 (14.8–18.2) 27.7 (26.2–29.2) 25.5 (24.6–26.3)
Human papillomavirus 0 94.8 (93.6–96.0) 100.0 – 97.8 (97.2–98.3) – –
≥1 5.2 (4.0–6.4) 0.0 – 2.3 (1.7–2.8) – –
≥2 4.7 (3.6–5.8) 0.0 – 2.0 (1.6–2.5) – –
Tick-borne encephalitis 0 76.1 (73.9–78.3) 71.7 (69.6–73.7) 73.6 (72.1–75.1) 91.5 (91.0–92.1)
≥1 23.9 (21.7–26.1) 28.3 (26.3–30.4) 26.4 (24.9–27.9) 8.5 (7.9–9.0)
≥2 22.8 (20.7–25.0) 27.3 (25.2–29.3) 25.3 (23.9–26.8) 7.9 (7.3–8.4)
≥3 19.8 (17.7–21.8) 24.3 (22.3–26.2) 22.3 (20.9–23.7) 6.3 (5.8–6.8)
Haemophilus influenzae type B 0 85.0 (83.1–86.8) 99.3 (98.9–99.7) 93.1 (92.2–94.0) 40.2 (39.2–41.2)
≥1 15.0 (13.2–16.9) 0.7 (0.3–1.1) 6.9 (6.0–7.8) 59.8 (58.8–60.8)
≥2 8.2 (6.8–9.6) 0.2 (0.0–0.3) 3.7 (3.0–4.3) 32.9 (31.9–33.8)
Influenza 0 99.3 (98.9–99.7) 97.9 (97.2–98.5) 98.5 (98.1–98.9) – –
≥1 0.7 (0.3–1.1) 2.1 (1.5–2.8) 1.5 (1.1–1.9) – –
≥2 0.0 – 0.2 (0.0–0.3) 0.1 (0.0–0.2) – –
Tuberculosis 0 57.6 (55.0–60.1) 65.7 (63.6–67.9) 62.2 (60.5–63.9) – –
≥1 42.5 (39.9–45.0) 34.3 (32.1–36.4) 37.8 (36.1–39.5) – –
≥2 8.1 (6.7–9.5) 8.4 (7.1–9.7) 8.3 (7.3–9.2) – –
Original article Swiss Med Wkly. 2014;144:w13955
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 8
also indicated that coverage increased steadily and quickly
until the 1982 birth cohort, where MCV coverage at one
dose was saturated at about 95%. Around 5% of the young
participants remained unvaccinated against measles. The
MCV coverage determined could also be used as a baseline
to measure the effectiveness of the FOPH measles elimina-
tion campaign, which will begin only in 2014.
Our results showed that, although the majority of the par-
ticipants believed measles is a dangerous disease and
measles vaccination made sense, less than half agreed with
compulsory measles immunisation. Many participants
were still unsure about HPV vaccination. Thus, we see that
more efforts could be invested in disseminating informa-
tion regarding the benefits of compulsory measles immun-
isation and HPV vaccination, particularly with the differen-
ce in perception between the linguistic regions and the two
age groups. This information could help the FOPH plan
their strategy for reaching their goals to eliminate measles
in Switzerland by 2015, such as vaccination policies in
the schools. Preliminary in-depth analysis of the SNVCS
2005–10 showed that teenagers living in the German-
speaking cantons that provided vaccination in the schools
with the help of a school nurse were significantly better
vaccinated with two doses of MMR than teenagers living
in the German-speaking cantons where the schools had not
offered this service [24]. The effectiveness of school-based
vaccinations has also been confirmed in many previous
studies [25–27].
Selection bias and the low participation level were major
limitations in the campaign. As those who participated in
this campaign were generally more concerned with their
health, the results do not necessarily reflect the general
population. Furthermore, there was a significant difference
between the proportions of males and females participating
in the campaign, as seen in table 1, confirming that women
were more concerned with their health than men. This dis-
crepancy, however, was consistent with the profiles of par-
ticipants in other vaccination coverage studies conducted
in the pharmacies [28–29]. Consequently, because of these
limitations, we did not feel the results should be weighted
to reflect the Swiss population, but only the participants
in the campaign. However, although not reported, cover-
age data were also poststratified by linguistic region, sex
and birth cohort; the weighted coverage rates were almost
identical to those reported here.
Additional problems affecting participation in the campaign
included: (1.) although reduced, the cost of CHF 19.00 was a
barrier for participation, and (2.) time of the implementation
of the campaign was also not ideal, as the population was per-
haps overwhelmed with information regarding the possible
outbreak of the swine influenza (H1N1) and its prevention
through vaccination during this period.
Direct promotion and high acceptance of an electronic central
immunisation registry would overcome some of these limita-
tions, but only if the participation level is high enough to re-
duce selection and nonresponse bias so that the results from
the data could be applicable to the general population.
Conclusion
Immunisation coverage data attained from this campaign is
the first attempt to determine coverage in the adult popula-
tion. Vaccine coverage for the basic recommended immun-
isations in the adult population in Switzerland is suboptim-
al, whereas vaccination coverage for vaccinations recom-
mended for travelling abroad is quite high. More efforts are
needed to vaccinate adolescents before they leave school,
since vaccinations that are not needed for travelling tend to
be forgotten.
Table 3: Distribution (%) of the responses to the questionnaire according to linguistic region, sex and age group. D, F and I are the German-, French- and Italian-speaking
regions, respectively.
All Linguistic region Sex Birth cohort
D F I Female Male 1967–1992 ≤1966
n = 1,011 n = 872 n = 10 n = 38 n = 671 n = 340 n = 327 n = 684
1. Do you think that measles is:
Dangerous 69.0 69.7 67.3 57.9 72.7 61.8 72.5 67.4
Not very dangerous 14.7 14.3 13.9 26.3 13.3 17.6 16.8 13.7
Not dangerous 2.5 2.6 2.0 0.0 2.7 2.1 2.4 2.5
Don't know 12.1 11.7 13.9 15.8 9.7 16.8 7.3 14.3
No answer 1.7 1.6 3.0 0.0 1.6 1.8 0.9 2.0
2. Do you think that vaccination against measles makes sense?
Yes 76.9 75.8 82.2 86.8 81.5 67.6 84.7 73.1
No 5.2 5.6 3.0 2.6 4.9 5.9 3.7 6.0
Don't know 16.5 17.3 11.9 10.5 12.2 25.0 11.0 19.2
No answer 1.4 1.3 3.0 0.0 1.3 1.5 0.6 1.8
3. Do you think that vaccination against measles should be mandatory?
Yes 43.7 42.8 49.5 50.0 45.5 47.4 40.3 42.0
No 31.2 31.8 24.8 34.2 31.9 29.7 27.2 33.0
Don't know 23.2 23.6 22.8 15.8 20.6 28.5 23.9 23.0
No answer 1.9 1.8 3.0 0.0 2.1 1.5 1.5 2.0
4. Do you think that vaccination against human HPV for young girls makes sense?
Yes 57.1 54.7 76.2 60.5 58.3 54.7 60.9 55.3
No 7.8 8.5 2.0 7.9 9.5 4.4 6.7 8.3
Don't know 33.8 35.7 18.8 31.6 31.0 39.4 31.8 34.8
No answer 1.3 1.1 3.0 0.0 1.2 1.5 0.6 1.6
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This campaign has shown that pharmacies have a potential
to make an impact in public health, such as vaccination
counselling, through their convenient hours and location.
It also shows the importance and feasibility of establishing
a central immunisation registry. Although the results from
this campaign cannot be generalised due to selection bias
and low participation, a well-established national immun-
isation registry with a high representative participation will
yield invaluable epidemiological evaluation, as well as im-
munisation coverage, as the potential has been demon-
strated with this small database.
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Figures (large format)
Figure 1
(a) Measles-containing vaccine (MCV) coverage for various birth cohorts at one and two doses; n represents the size of the birth cohort. (b)
Number of participants according to year and birth cohort ≤1966, 1967‒1992 and ≤1992. Starting in 1993 the curve is flat since no new
participants were considered. (c) MCV coverage over time for birth cohorts ≤1966, 1967–1992 and ≤1992. Arrows labelled with (+) indicate
when changes to the measles / measles-mumps-rubella recommendations were made in the Swiss Immunization Schedule and arrows labelled
with (*) show the occurrences of large measles outbreaks in Switzerland that were published. The bars on the coverage data represent Wald
confidence intervals.
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